close
close

Ceretrieve touts positive data from its aspiration catheter study

Posted on by darion

According to GlobalData epidemiologists, by 2027 there will be 96,246,493 cases of acute ischemic stroke worldwide. Source: Peakstock via Shutterstock.

Ceretrieve announced positive results from a study that showed the aspiration catheter removed clots by completely restoring blood flow in one pass.

The Ceretrieve aspiration catheter is a medical device used to remove blood clots from blood vessels in the body. It works by using a vacuum or suction effect to draw away unwanted material, helping to treat a stroke or deep vein thrombosis.

The first human study showed that 80% of complete or near complete perfusion rate was achieved. The study included two generations of the device, with the improved Gen 2 device demonstrating 100% complete/almost complete perfusion in all treated patients and 83% first-pass complete perfusion (FPE mTICI 3). This exceeds the 30-40% rate currently applicable to gold-standard devices, according to the May 28 announcement.

The study included 20 patients who had suffered an acute ischemic stroke (AIS) due to occlusion of large intracranial vessels (LVO) and were eligible for thrombectomy – a medical procedure that involves removing a blood clot from a blood vessel – within 24 hours of the onset of symptoms. According to GlobalData epidemiologists, by 2027 there will be 96,246,493 cases of AIS worldwide.

The first neurothrombectomy performed using this device was performed by Shady Jashan, director of the Department of Interventional Neuroradiology at Israel’s Galilee Medical Center.

Jashan said: “Our experience in the FIH trials has shown that the Ceretrieve device quickly enables complete clot ingestion on the first pass, even for the most difficult clots and anatomy. This could significantly improve clinical outcomes for patients.”

Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain a competitive advantage.

Company Profile – free sample

You will receive a download email shortly

We are sure of the exceptional quality of our company profiles. However, we want you to make the most beneficial decision for your business, which is why we offer a free sample, which you can download by submitting the form below

By GlobalData







Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information about your rights in relation to your personal data and how you can unsubscribe from future subscriptions marketing messages. Our services are intended for corporate subscribers and you warrant that the email address you submit is your corporate email address.

According to GlobalData’s medical device pipeline database, 20 aspiration catheters are in various stages of development around the world. Ceretrieve is one of the leading players in the space industry, alongside HeMo Bioengineering, RapidPulse and Route 92 Medica.

Last month, medical device giant Johnson & Johnson (J&J) announced the launch of the Cereglide aspiration catheter in Europe, adding to its portfolio of stroke solutions that includes a revascularization device and a clot extractor.

Additionally, Expanse ICE’s aspiration thrombectomy system ICE Aspiration System received U.S. Food and Drug Administration (FDA) 510(k) clearance in April 2024. It features a dual-lumen design that creates patented Surge Aspiration technology, a novel cyclic aspiration type on distal end of the catheter.